Literature DB >> 27647406

[Mortality and survival analysis of esophageal cancer in China].

S W Zhang1, R S Zheng1, T T Zuo1, H M Zeng1, W Q Chen1, J He1.   

Abstract

OBJECTIVE: To estimate the nationwide mortality of esophageal cancer in China in 2012, to investigate the trends of the disease, and to provide support data for esophageal cancer prevention and control in China.
METHODS: Data of population-based cancer registry of China were extracted by sex and geographical area. Joinpoint software was used to analyze the trends of esophageal cancer from 2000 to 2011 using the continuous data of 22 cancer registries. Average annual percentage change rates (AAPC) were calculated, and 17 cancer registries data during 2003-2005 were analyzed.
RESULTS: In 2012, there were estimated 210.9 thousand new cases of esophageal cancer death in China, with 149 thousand in males and 61.9 thousand in females, accounting for 9.65% of overall cancer death. The crude mortality rate of esophageal cancer in 2012 was 15.58 per 100 000, accounting for the fourth-leading cause of overall cancer deaths. The age-standardized mortality rates by world population and China population were 10.67 per 100 000 and 10.62 per 100 000, respectively. The cumulative mortality rate for age 0-74 was 1.28%. The age-specific mortality rates were increasing with age, and there was a sharp increase after 50 years of age. From 2000 to 2011, there was a slight decreasing trend for crude mortality rate, with the AAPC of -1.1% (95% CI: -1.8% to -0.5%). However, the age standardized mortality rates were decreasing significantly with the AAPC of -4.6% (95% CI: -5.7% to -3.6%). The AAPCs for age-standardized esophageal cancer mortality were -3.8% in urban areas and -2.4% in rural areas. For combined 5-year age standardized relative survival was 20.9% (95%CI: 20.2% to 21.7%) and the 1-, 3- and 5-year observed survival rates were 54.0%, 25.5%, 18.4%, respectively.
CONCLUSION: There is still a heavy burden of esophageal cancer in China. Prevention and early diagnosis of the disease in esophageal cancer high-risk areas is very essential.

Entities:  

Mesh:

Year:  2016        PMID: 27647406     DOI: 10.3760/cma.j.issn.0253-3766.2016.09.014

Source DB:  PubMed          Journal:  Zhonghua Zhong Liu Za Zhi        ISSN: 0253-3766


  17 in total

Review 1.  Chinese expert consensus on mediastinal lymph node dissection in esophagectomy for esophageal cancer (2017 edition).

Authors:  Hui Li; Wentao Fang; Zhentao Yu; Yousheng Mao; Longqi Chen; Jie He; Tiehua Rong; Chun Chen; Haiquan Chen; Keneng Chen; Ming Du; Yongtao Han; Jian Hu; Jianhua Fu; Xiaobin Hou; Taiqian Gong; Yin Li; Junfeng Liu; Shuoyan Liu; Lijie Tan; Hui Tian; Qun Wang; Jiaqing Xiang; Meiqing Xu; Xin Ye; Bin You; Renquan Zhang; Yan Zhao
Journal:  J Thorac Dis       Date:  2018-04       Impact factor: 2.895

2.  Annotating Early Esophageal Cancers Based on Two Saliency Levels of Gastroscopic Images.

Authors:  Dingyun Liu; Nini Rao; Xinming Mei; Hongxiu Jiang; Quanchi Li; ChengSi Luo; Qian Li; Chengshi Zeng; Bing Zeng; Tao Gan
Journal:  J Med Syst       Date:  2018-10-16       Impact factor: 4.460

3.  Combined Mean Corpuscular Hemoglobin, Fibrinogen, and Albumin (MF-A) Is a Novel Prognostic Marker in Patients with Resectable Esophageal Squamous Cell Carcinoma.

Authors:  Linlin Liang; Fangfang Liu; Wenlei Yang; Wei Yang; Lei Chen; Yu He; Zhen Liu; Liqun Zhang; Fan Zhang; Fen Cai; Huawen Xu; Miaoping Lin; Mengfei Liu; Yaqi Pan; Ying Liu; Zhe Hu; Huanyu Chen; Zhonghu He; Yang Ke
Journal:  Ann Surg Oncol       Date:  2022-02-18       Impact factor: 4.339

4.  A comparative study on the efficacy of fast-track surgery in the treatment of esophageal cancer patients combined with metabolic syndrome.

Authors:  Ziteng Zhang; Haijun Li; Chunzhang Yan; Baobin Xu; Ronghang Hu; Ming Ma; Haixiang Wei; Yanhong Meng
Journal:  Oncol Lett       Date:  2017-08-17       Impact factor: 2.967

5.  High expression of Collagen Triple Helix Repeat Containing 1 (CTHRC1) facilitates progression of oesophageal squamous cell carcinoma through MAPK/MEK/ERK/FRA-1 activation.

Authors:  Chunni Wang; Zitong Li; Fei Shao; Xueying Yang; Xiaoli Feng; Susheng Shi; Yibo Gao; Jie He
Journal:  J Exp Clin Cancer Res       Date:  2017-06-23

6.  Characteristics of the local recurrence pattern after curative resection and values in target region delineation in postoperative radiotherapy for lower thoracic esophageal squamous cell cancer.

Authors:  Jun Liu; Xuwei Cai; Qi Liu; Hongxuan Li; Yan Cheng; Xiaolong Fu
Journal:  Thorac Cancer       Date:  2017-09-23       Impact factor: 3.500

7.  Exploration of the methods of establishing the minimum clinical important difference based on anchor and its application in the quality of life measurement scale QLICP-ES (V2.0) for esophageal cancer.

Authors:  Dandan Ren; Ting Wu; Chonghua Wan; Gaofeng Li; Yanbo Qi; Yujing Fang; Jiudi Zhong
Journal:  Health Qual Life Outcomes       Date:  2021-07-02       Impact factor: 3.186

8.  Analysis of risk factors for post-operative complications and prognostic predictors of disease recurrence following definitive treatment of patients with esophageal cancer from two medical centers in Northwest China.

Authors:  Jichang Wang; Boxiang Zhang; Jinying Meng; Guodong Xiao; Xiang Li; Gang Li; Sida Qin; Ning Du; Jia Zhang; Jing Zhang; Chongwen Xu; Shou-Ching Tang; Rui Liang; Hong Ren; Xin Sun
Journal:  Exp Ther Med       Date:  2017-07-25       Impact factor: 2.447

9.  Treatment of esophageal cancer with radiation therapy -a pan-Chinese survey of radiation oncologists.

Authors:  Yun Zhang; Jing Liu; Wencheng Zhang; Weiye Deng; Jinbo Yue
Journal:  Oncotarget       Date:  2017-05-23

10.  Sulforaphene induces apoptosis and inhibits the invasion of esophageal cancer cells through MSK2/CREB/Bcl-2 and cadherin pathway in vivo and in vitro.

Authors:  Chengjuan Zhang; Junxia Zhang; Qiong Wu; Benling Xu; Guoguo Jin; Yan Qiao; Simin Zhao; Yang Yang; Jinwen Shang; Xiaofang Li; Kangdong Liu
Journal:  Cancer Cell Int       Date:  2019-12-19       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.